ClinicalTrials.gg
RecruitingNCT07190443AURAUpdated Sep 29, 2025

Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)

A Phase 3 interventional study of Endocrine therapy + Abemaciclib and Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen in Breast Cancer, Locoregional Recurrence and Abemaciclib, sponsored by Japanese Foundation for Cancer Research. Recruiting at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-29.

Sponsored by Japanese Foundation for Cancer Research · Phase 3, Interventional, and Treatment

How we know · 11 judgments

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Feb 2025, registered Sep 2025).
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Planned enrollment
10th of 55
290 · median 120
Started
2025
with 1 other
Phase 3
11 of 55
2 open now
Primary completion
2034-02
later than 33 of 33 live
Registered
48th of 55
by date

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 10th largest by planned enrollment, is one of 2 that started in 2025, is one of 11 in phase 3, reaches primary completion later than 33 of the 33 other live ones, and was the 48th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The JCOG2313 trial is a multicenter, randomized, phase III study designed to evaluate the efficacy and safety of adjuvant abemaciclib in combination with endocrine therapy versus endocrine therapy alone in patients with hormone receptor (HR)-positive, HER2-negative breast cancer who have undergone curative treatment for their first locoregional recurrence (LRR).

Although HR-positive, HER2-negative breast cancer generally has a favorable prognosis, LRR-such as ipsilateral breast tumor recurrence (IBTR), chest wall recurrence, or regional lymph node recurrence-remains a clinically significant event that increases the risk of distant metastasis. While endocrine therapy is standard in this setting, the benefit of adding chemotherapy or other agents remains unclear, and treatment strategies vary widely.

Abemaciclib, a CDK4/6 inhibitor, has shown survival benefit in the adjuvant setting for high-risk early breast cancer. However, its role in post-LRR adjuvant treatment has not been evaluated in a randomized setting. This study aims to determine whether the addition of abemaciclib to endocrine therapy can improve invasive disease-free survival (IDFS) in patients after LRR.

Eligible patients are randomized 1:1 to receive either endocrine therapy alone or endocrine therapy plus abemaciclib (150 mg twice daily for 2 years). The primary endpoint is IDFS. Secondary endpoints include distant recurrence-free survival, breast cancer-specific survival, overall survival, and safety. A total of 290 patients will be enrolled. Randomization is stratified by site of recurrence, endocrine resistance, perioperative chemotherapy, and institution.

Additionally, a prospective ancillary study will assess circulating tumor DNA (ctDNA) as a biomarker for molecular residual disease (MRD). Plasma samples will be collected at predefined time points to evaluate the prognostic and predictive value of ctDNA for relapse and treatment response.

The JCOG2313 trial addresses an unmet need in the management of HR-positive, HER2-negative LRR and may contribute to the establishment of a new standard systemic therapy and personalized monitoring strategies.

03

Conditions studied

  • Breast Cancer
  • Locoregional Recurrence
  • Abemaciclib
  • Endocrine Therapy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient has been diagnosed with the first locoregional recurrence (LRR) after receiving definitive treatment for primary breast cancer. LRR includes one or more of the following:

    (i) Ipsilateral breast tumor recurrence (ii) Ipsilateral chest wall recurrence (iii) Regional lymph node recurrence

  2. At least one LRR lesion must be confirmed by a , surgical specimen, or cell block from cytology, and must meet all of the following:

    (i) confirmed as invasive breast cancer, or diagnosed as breast cancer in a cytology cell block (in cases where only a cell block is available, the initial primary breast cancer must have been invasive).

    (ii) Hormone receptor (HR) expression is positive. (iii) expression is negative.

    ※ If multiple lesions are pathologically evaluated and any lesion is HR-negative or HER2-positive, the patient is ineligible.

  3. No prior diagnosis of distant of breast cancer.
  4. Imaging assessment before registration confirms:

    No lymph nodes ≥10 mm in short axis No evidence of distant metastasis

  5. Age ≥18 years at the time of registration.
  6. Performance Status of 0 or 1.
  7. Chemotherapy for LRR is allowed prior to enrollment.
  8. The patient does not have bilateral breast cancer.
  9. No prior history of treatment with CDK4/6 inhibitors.
  10. Written has been obtained for participation in this clinical trial.

Exclusion criteria

Exclusion Criteria:

  1. Presence of active double cancer (synchronous requiring treatment).
  2. Ongoing infectious disease requiring systemic therapy.
  3. Fever ≥38.0°C at the time of registration.
  4. Women who are pregnant, possibly pregnant, within 28 days postpartum, or breastfeeding; men whose partners intend to become pregnant.
  5. Psychiatric illness or symptoms that interfere with daily living and may compromise trial participation.
  6. Ongoing systemic administration (oral or IV) of equivalent to ≥10 mg/day of prednisolone or other agents.
  7. Unstable angina (developed or worsened within the past 3 weeks) or myocardial infarction within the past 6 months.
  8. Uncontrolled hypertension.
  9. Uncontrolled diabetes mellitus despite continuous insulin or oral antidiabetic therapy.
  10. Positive for HBs antigen or antibodies (Patients positive for HCV antibodies are not excluded if HCV-RNA is undetectable.)
  11. Positive for antibodies (HIV testing is not mandatory.)
  12. Presence of interstitial pneumonia, pulmonary fibrosis, or severe emphysema as diagnosed by chest CT.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
290 participants (estimated)

Study arms

  • Active comparator
    Standard endocrine therapy (Arm A)

    Participants in Arm A will receive standard endocrine therapy alone as adjuvant treatment following curative-intent local therapy for first locoregional recurrence (LRR) of hormone receptor (HR)-positive, HER2-negative breast cancer. No CDK4/6 inhibitor is administered in this arm.

    Drug: Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen

  • Experimental
    Endocrine therapy in combination with abemaciclib (Arm B)

    Participants in Arm B will receive endocrine therapy in combination with abemaciclib following curative-intent local treatment for first LRR of HR-positive, HER2-negative breast cancer.

    Drug: Endocrine therapy + Abemaciclib

Interventions

  • DrugEndocrine therapy + Abemaciclib

    Drug page: AbemaciclibStudies of AbemaciclibAbemaciclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This intervention consists of adjuvant endocrine therapy in combination with abemaciclib, a CDK4/6 inhibitor, administered to patients with HR-positive, HER2-negative breast cancer who have undergone curative-intent local treatment for their first LRR, including ipsilateral breast tumor recurrence, chest wall recurrence, or regional lymph node recurrence. Abemaciclib is given orally at a dose of 150 mg twice daily for a maximum of 2 years, in accordance with the approved dosing regimen in the adjuvant setting. The choice of endocrine therapy-aromatase inhibitor, tamoxifen, or tamoxifen plus ovarian function suppression-is determined based on menopausal status and prior treatment history.

  • DrugEndocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen

    Drug pages: LetrozoleStudies of LetrozoleLetrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ExemestaneStudies of ExemestaneExemestane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TamoxifenStudies of TamoxifenTamoxifen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This intervention consists of adjuvant endocrine therapy alone in patients with HR-positive, HER2-negative breast cancer who have undergone curative treatment for their first LRR, including ipsilateral breast tumor recurrence, chest wall recurrence, or regional lymph node recurrence. The choice of endocrine therapy (aromatase inhibitor, tamoxifen, or tamoxifen plus ovarian function suppression) is determined based on the patient's menopausal status and prior treatment history, as specified in the protocol. Treatment is continued for five years or until disease recurrence, unacceptable toxicity, or withdrawal of consent. This intervention does not include CDK4/6 inhibitors.

06

What researchers measure

Primary outcomes

  1. Invasive disease-free survival

    Defined as the time from randomization to the first occurrence of one of the following events: * Recurrence of invasive breast cancer in the ipsilateral breast, chest wall, or regional lymph nodes (locoregional recurrence); * Distant recurrence of breast cancer (metastatic disease); * Invasive contralateral breast cancer; * Second primary invasive non-breast cancer (excluding non-melanoma skin cancer and in situ cervical cancer); * Death from any cause. Patients who have not experienced any of the above events will be censored at the date of last disease assessment.

    Time frame: Up to 9 years (4 years of accrual and 5 years of follow-up)

Secondary outcomes

  1. Distant recurrence-free survival

    Distant Recurrence-Free Survival (DRFS) is defined as the time from randomization to the first occurrence of distant recurrence of breast cancer or death from any cause, whichever occurs first. Distant recurrence is defined as radiographically or pathologically confirmed metastatic disease outside of the locoregional area. Patients without events will be censored at the date of last disease assessment. DRFS is evaluated as a secondary endpoint to assess the effectiveness of treatment in preventing distant metastatic progression.

    Time frame: Up to 9 years (4 years of accrual and 5 years of follow-up)

  2. Breast cancer-specific survival

    Breast Cancer-Specific Survival (BCSS) is defined as the time from randomization to death due to breast cancer. Deaths from other causes (non-breast cancer-related) will be considered competing events and will be censored at the time of death. Patients who are alive at the time of analysis or lost to follow-up will be censored at the date of last known contact. BCSS is included as a secondary endpoint to evaluate the disease-specific mortality benefit of the intervention.

    Time frame: Up to 9 years (4 years of accrual and 5 years of follow-up)

  3. Overall survival

    Overall Survival (OS) is defined as the time from randomization to death from any cause. Patients who are alive at the time of analysis or lost to follow-up will be censored at the date of last known contact. OS will be assessed as a secondary endpoint to evaluate the overall survival benefit of adjuvant abemaciclib in combination with endocrine therapy in the post-recurrence setting.

    Time frame: Up to 9 years (4 years of accrual and 5 years of follow-up)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Plans for sharing IPD have not been finalized. Data sharing may be considered in the future pending appropriate ethical and regulatory approvals.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2034, 107 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 107 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Sep 24, 2025
StartActual
Feb 7, 2025
Primary completionEst.
Feb 6, 2034
CompletionEst.
Feb 6, 2035
Last update
Sep 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07190443
Lead sponsor
Japanese Foundation for Cancer Research
Collaborators
Japan Clinical Oncology Group
Responsible party
Yukinori Ozaki (Head Physician, Japanese Foundation for Cancer Research) — Principal investigator
First posted
Sep 24, 2025
Start date
Feb 7, 2025
Primary completion
Feb 6, 2034 (estimated)
Completion
Feb 6, 2035 (estimated)
Last update
Sep 29, 2025

Study contacts

Yukinori Ozaki, MD. PhD.
Contact
yukinori.ozaki@jfcr.or.jp
+81335200111

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion